Wells Fargo Reiterates Equal-Weight Rating on Regeneron Pharmaceuticals, Inc. (REGN)

Market Context

Regeneron Pharmaceuticals, Inc. operates in the Healthcare sector. The stock currently trades at $961.26 with a market capitalization of $77.2B. The stock has gained 18.3% over the past 52 weeks.

Analyst coverage from Wells Fargo provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Regeneron Pharmaceuticals, Inc.

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Regeneron Pharmaceuticals, Inc.

Among the 10 most recent ratings: 5 Buy, 5 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Nov 02, 2026	Truist Securities	Buy	N/A
Nov 02, 2026	RBC Capital	Sector Perform	N/A
Nov 02, 2026	Morgan Stanley	Equal-Weight	N/A
Nov 02, 2026	Bernstein	Market Perform	N/A
Nov 02, 2026	Leerink Partners	Market Perform	N/A

Related Tools: Analyst Ratings Dashboard | View REGN Stock Page